Important: Most data come from the originating laboratory and collaborators; independent replication is limited, and pharmacokinetic, toxicology and dosing data for humans do not exist. Not a cancer treatment.
Overview
PNC-27 is a 32-residue chimeric peptide designed at SUNY Downstate in the early 2000s. It fuses residues 12–26 of the tumour-suppressor protein p53 — the segment that binds the p53 regulator MDM2/HDM-2 — to penetratin, a 17-residue cell-penetrating sequence from the Drosophila Antennapedia homeodomain. The design intent was to disrupt the p53–HDM-2 interaction inside cancer cells; what the Pincus laboratory found instead was that PNC-27 kills cancer cells from the outside, by binding HDM-2 that is aberrantly displayed in the plasma membrane of transformed cells and punching pores through it.
Across more than two decades of preclinical work, PNC-27 has induced rapid necrosis of pancreatic, breast, colon, melanoma and leukaemia cell lines, spared untransformed cells that lack membrane HDM-2, and shrunk xenografts in mice. It remains a laboratory compound: no human trial has been registered or published, and it is not an approved drug anywhere.
Mechanism of Action
Cancer cells frequently express HDM-2 (the human MDM2 protein) not only in the nucleus but in the plasma membrane; untransformed cells do not. The p53(12–26) segment of PNC-27 binds this membrane HDM-2, anchoring the peptide at the cell surface, while the penetratin segment inserts into the lipid bilayer. Multiple PNC-27 molecules then assemble into transmembrane pores of roughly 1–2 µm, causing rapid loss of membrane integrity, LDH release and necrotic cell death within hours — a mechanism independent of p53 status, caspase activation or apoptosis.
The selectivity argument rests on membrane HDM-2: cells engineered to express HDM-2 at the surface become sensitive, HDM-2 knockdown confers resistance, and normal fibroblasts, hepatocytes and haematopoietic progenitors are spared. Later work reported an additional interaction with mitochondrial membranes in cancer cells, contributing to mitochondrial disruption. Because the mechanism is physical pore formation rather than a signalling cascade, cells do not develop the usual pathway-based resistance in vitro.
Research Evidence
- PNC-27 adopts the HDM-2-binding conformation of p53 and kills cancer cells by binding HDM-2 in their plasma membranes, forming transmembrane pores; untransformed cells lacking membrane HDM-2 are spared (Sarafraz-Yazdi et al., PNAS 2010; PMID 20080680)
- Peptides from the p53 MDM-2-binding domain, designed from conformational analysis, were selectively cytotoxic to transformed cells — the founding study of the PNC series (Kanovsky et al., PNAS 2001; PMID 11606716)
- PNC-27 induced necrosis in acute myeloid and lymphoblastic leukaemia cells that express membrane HDM-2, but not in normal haematopoietic cells (Sookraj et al., 2010; PMID 20182728)
- PNC-27 causes mitochondrial membrane disruption in addition to plasma-membrane pore formation in cancer cells (Krzesaj et al., Ann Clin Lab Sci 2024; PMID 38802154)
- A 2022 review consolidated two decades of PNC-27 data: selective membranolysis across solid-tumour and leukaemia lines and xenograft regression, with no human trial to date (Biomedicines 2022; PMID 35625682)
Bottom line: Two decades of promising lab and mouse data, no human trial, no approval. Anyone selling PNC-27 as a cancer therapy is going far beyond the evidence. Research-only.
Evidence & References
The full compound profile lists the evidence level, the studies behind each claim with PubMed links, and the adverse-effect record. Compound Review does not publish dosing protocols.
Sourcing & Quality
PNC-27 is available from Purgo Labs with third-party COA verification and research-grade purity standards. View PNC-27 at Purgo Labs.